共 11 条
- [1] A composite blood biomarker including AKR1B10 and cytokeratin 18 performs well in the diagnosis of NASH, advanced hepatic fibrosis, and high-risk NASHDIABETOLOGIA, 2023, 66 (SUPPL 1) : S509 - S509Lee, D.Oh, B. -C.Kim, S.
- [2] Thrombospondin-2 as a new biomarker for at risk NASH and advanced fibrosis in a large multicentric European cohortJOURNAL OF HEPATOLOGY, 2023, 78 : S652 - S653Ratziu, VladSurabattula, RambabuBugianesi, ElisabettaSchattenberg, JornPonnaiah, MaharajahRosso, ChiaraArmandi, AngeloMyneni, SudhaPais, RalucaKara, LeilaSchuppan, Detlef
- [3] YPrevalence and Risk Factors of NAFLD, High-Risk NASH, and Fibrosis Among Lean US AdultsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S1055 - S1056Kalligeros, MarkosVassilopoulos, StephanosVassilopoulos, AthanasiosShehadeh, FadiLazaridou, IngridMylonakis, EleftheriosPromrat, KittichaiWands, Jack R.
- [4] Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk populationATHEROSCLEROSIS, 2018, 278 : 82 - 90Wargny, MatthieuDucluzeau, Pierre-HenriPetit, Jean-MichelLe May, CedricSmati, SarraArnaud, LuciePichelin, MatthieuBouillet, BenjaminLannes, AdrienBlanchet, OdileLefebvre, PhilippeFrancque, SvenVan Gaal, LucStaels, BartVerges, BrunoBoursier, JeromeCariou, Bertrand
- [5] Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular riskAMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2021, 321 (03): : G252 - G261Delgado, Graciela E.Kleber, Marcus E.Moissl, Angela P.Yazdani, BabakKusnik, AlexanderEbert, Matthias P.Maerz, WinfriedKraemer, Bernhard K.Lammert, AlexanderTeufel, Andreas
- [6] PLASMA AKR1B10 IS THE BIOMARKER THAT SHOWS THE BEST PERFORMANCE IN THE DIAGNOSIS OF NASH AND HEPATIC FIBROSIS IN COMBINATION WITH CURRENTLY AVAILABLE DIAGNOSTIC MARKERSHEPATOLOGY, 2022, 76 : S795 - S796Lee, DaehoChoi, Seung Joon
- [7] PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD populationJOURNAL OF HEPATOLOGY, 2022, 77 : S431 - S432Tang, Liang-JieLi, GangEslam, MohammedZhu, Pei-WuChen, Sui-DanLeung, Howard Ho-WaiHuang, Ou-YangWong, Grace Lai-HungZhou, Yu-JieKarsdal, MortenLeeming, DianaByrne, ChrisTargher, GiovanniGeorge, JacobWong, Vincent Wai-SunZheng, Ming-Hua
- [8] High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism AbnormalitiesDIAGNOSTICS, 2024, 14 (04)Israel-Biet, DominiqueBernardinello, NicolPastre, JeanTana, ClaudioSpagnolo, Paolo
- [9] HIGH-FIELD MR-SPECTROSCOPY IN PATIENTS WITH NAFLD ALLOWS NOVEL INSIGHTS IN ALTERED HEPATIC LIPID AND ENERGY METABOLISM WITH POTENTIAL DISTINCTION OF NASH AND ADVANCED FIBROSISJOURNAL OF HEPATOLOGY, 2013, 58 : S551 - S551Traussnigg, S.Halilbasic, E.Kienbacher, C.Gajdosik, M.Valkovic, L.Chmelik, M.Stift, J.Hofer, H.Steindl-Munda, P.Kazemi-Shirazi, L.Peck-Radosavljevic, M.Ferenci, P.BaSsalamah, A.Wrba, F.Krebs, M.Trattnig, S.Krssak, M.Trauner, M.
- [10] CORRECTED T1 HAS THE POTENTIAL TO IMPROVE SAFETY AND ACCURATE DIAGNOSIS OF HIGH-RISK NASH TO REDUCE UNNECESSARY BIOPSY IN THE NAFLD DIAGNOSTIC PATHWAYHEPATOLOGY, 2022, 76 : S605 - S607French, MarikaAndersson, AnneliShumbayawonda, ElizabethTonev, Dimitar VelkovBanerjee, RajarshiBackhaus, JohannaCoenraad, Minneke J.Schaapman, Jelte J.Castelo-Branco, MiguelCuthbertson, DanByrne, Christopher D.Patel, JanishaMiller, Michael H.Barclay, StephenAjaz, SaimaAgarwal, KoshForton, DanielYalcin, MetinFraser, AndrewDollinger, MatthiasLamb, Hildo J.